Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Suspended 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3978Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Stomach Neoplasms 2109Rectal Neoplasms 1676Colonic Neoplasms 1629Esophageal Neoplasms 1312Liver Neoplasms 878Neoplasms 633Breast Neoplasms 596Cholangiocarcinoma 525Gastrointestinal Neoplasms 468Neoplasm Metastasis 456Esophageal Squamous Cell Carcinoma 434Lung Neoplasms 422Biliary Tract Neoplasms 277Prostatic Neoplasms 270Ovarian Neoplasms 235Barrett Esophagus 224Adenocarcinoma Of Esophagus 202Gallbladder Neoplasms 191Head and Neck Neoplasms 185Carcinoma, Non-Small-Cell Lung 185Gastrointestinal Stromal Tumors 180Anus Neoplasms 179Recurrence 168Melanoma 162Adenocarcinoma 156Uterine Cervical Neoplasms 153Bile Duct Neoplasms 153

Interventions

Oxaliplatin 2tislelizumab 1sintilimab 1donafenib 1Immunotherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Biliary Tract Carcinoma × Gastrointestinal × Clear all
NCT06199882 2024-10-15

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Zhejiang Cancer Hospital

Phase 2 Suspended
34 enrolled
Gastrointestinal

Biliary Tract Carcinoma

NCT04984980 2023-01-26

Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

Fudan University

Phase 2 Unknown
37 enrolled
Gastrointestinal

Biliary Tract Carcinoma

NCT04979663 2021-08-09

GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

Fudan University

Phase 1/2 Unknown
10 enrolled
Gastrointestinal

Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡